Medizinische Klinik III, Universität Leipzig, Medizinische Fakultät, Leipzig, Germany.
Helmholtz Institute for Metabolic, Obesity and Vascular Research of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
Arthritis Rheumatol. 2024 Dec;76(12):1719-1729. doi: 10.1002/art.42960. Epub 2024 Sep 4.
CD4CD8 T cells are increased in patients with rheumatoid arthritis (RA). They are not only associated with joint erosions in established disease but are also present in the preclinical stages of RA. This study aims to further investigate their expansion in the context of T cell clonality in patients with RA, as well as their responsiveness to T cell-targeted treatment.
Single-cell RNA (scRNA) and single-cell T cell receptor (TCR) sequencing data were used to determine coreceptor expression and TCR sequences to assess the clonality of CD4CD8 T cells in patients with RA (n = 3) and healthy controls (n = 2). Peripheral CD4CD8 T cells and their subpopulations were measured in patients with RA (n = 53), patients with psoriatic arthritis (PsA; n = 52), and healthy donors (n = 50) using flow cytometry. In addition, changes in CD4CD8 T cell frequency were prospectively observed in patients with RA receiving therapy with abatacept for 12 weeks.
We observed an increase of CD4 T cells expressing CD8α in patients with RA, both in comparison to patients with PsA and healthy controls. Clonality analysis revealed that these CD4CD8α T cells are part of large T cell clones, which cluster separately from CD4CD8 T cell clones in the scRNA sequencing (scRNA-seq) gene expression analysis. Treatment with abatacept significantly reduced the frequency of peripheral CD4CD8α T cells, and this was linked to reduction in disease activity.
In patients with RA, clonal expansion of CD4 T cell culminates in the emergence of peripheral CD4CD8α T cells, which are associated with disease activity and diminished upon abatacept treatment and could contribute to disease pathogenesis.
CD4CD8 T 细胞在类风湿关节炎(RA)患者中增加。它们不仅与已确诊疾病中的关节侵蚀有关,而且也存在于 RA 的临床前阶段。本研究旨在进一步研究它们在 RA 患者的 T 细胞克隆性背景下的扩张情况,以及它们对 T 细胞靶向治疗的反应性。
使用单细胞 RNA(scRNA)和单细胞 T 细胞受体(TCR)测序数据来确定共受体表达和 TCR 序列,以评估 RA 患者(n = 3)和健康对照者(n = 2)的 CD4CD8 T 细胞的克隆性。使用流式细胞术在 RA 患者(n = 53)、银屑病关节炎(PsA;n = 52)患者和健康供体(n = 50)中测量外周血 CD4CD8 T 细胞及其亚群。此外,前瞻性观察接受阿巴西普治疗 12 周的 RA 患者中 CD4CD8 T 细胞频率的变化。
我们观察到 RA 患者中表达 CD8α 的 CD4 T 细胞增加,与 PsA 患者和健康对照者相比均增加。克隆性分析显示,这些 CD4CD8α T 细胞是大 T 细胞克隆的一部分,它们在 scRNA 测序(scRNA-seq)基因表达分析中与 CD4CD8 T 细胞克隆分开聚类。阿巴西普治疗显著降低了外周血 CD4CD8α T 细胞的频率,这与疾病活动度降低有关。
在 RA 患者中,CD4 T 细胞的克隆扩增导致外周血 CD4CD8α T 细胞的出现,这些细胞与疾病活动度相关,在阿巴西普治疗后减少,并可能有助于疾病发病机制。